Filing Flows › BioMarin Pharmaceutical (BMRN) › Q2 2025
BioMarin Pharmaceutical (BMRN) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 5, 2025
BioMarin Pharmaceutical (BMRN) reported revenue of $825M for the second quarter 2025 (Q2 2025), +16% from a year earlier and +11% from the quarter before. Operating margin was 33.5%, net earnings $241M (29.1% of revenue).
BioMarin Pharmaceutical, Q2 2025: revenue $825M (+16% year over year), operating margin 33.5%, net earnings $241M, operating cash flow $185M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $825M | +11% | +16% |
| Operating profit | $277M | +24% | +130% |
| Net earnings | $241M | +30% | +124% |
| Operating cash flow | $185M | +6% | +56% |
| Free cash flow | $168M | +7% | +73% |
What changed
Revenue was $825.4M in Q2 2025, up 16% year over year and up 11% from the previous quarter. VOXZOGO was the largest line at 27% of revenue. VOXZOGO added $37.5M year over year (up 20%), 33% of the total change. KUVAN declined 5%.
Operating profit was $276.9M, a 33.5% margin (up 16.6 points year over year). Of the extra revenue versus a year earlier, 138% reached operating profit, above the 17% margin then. Total costs fell 7% while revenue rose 16%. The fastest-growing cost line was Cost of revenue (+15%). Net earnings were $240.5M, up 124% year over year. The effective tax rate was 19.2%.
Operating cash flow was $185.3M (up 56% year over year), 77% of net earnings. Non-cash charges added back $18.6M of depreciation and amortization and $47.5M of share-based compensation. Working capital and other items used $121.4M. Capital expenditures of $17.1M left free cash flow of $168.2M.
Questions
What was BioMarin Pharmaceutical's revenue in the second quarter 2025?
BioMarin Pharmaceutical (BMRN) reported revenue of $825M for the second quarter 2025 (Q2 2025), +16% from a year earlier and +11% from the quarter before.
Was BioMarin Pharmaceutical profitable in the second quarter 2025?
Operating profit was $277M (33.5% of revenue) and net earnings $241M.